Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03530397 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
A Phase 1 study of Selected Advanced Solid Tumors, sponsored by MedImmune.
- Active
- Registry status
- Phase 1
- Development phase
- 401
- Enrollment target
- 20
- Study locations
NCT03530397: Active Phase 1 study of Selected Advanced Solid Tumors, sponsored by MedImmune.
NCT03530397 is a Phase 1 study of Selected Advanced Solid Tumors that is active but no longer recruiting, run by MedImmune. The registered enrollment target is 401 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (568% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03530397, a Phase 1 study of Selected Advanced Solid Tumors, is active but no longer recruiting, sponsored by MedImmune.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 401 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate MEDI5752 and carboplatin and pemetrexed or paclitaxel or nab-paclitaxel in adult subjects with advanced solid tumors, when administered as a single agent or combined with chemotherapy.
Primary Outcome
The primary endpoint is as assessed by the number of subjects experiencing adverse events (AEs) graded per NCI CTCAE v4.03
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Carboplatin
- DRUG Pemetrexed
- BIOLOGICAL MEDI5752
- DRUG Paclitaxel or Nab-Paclitaxel
Study Locations (20)
Other
- Research Site - Melbourne
- Research Site - Melbourne
- Research Site - Randwick
- Research Site - Bordeaux
- Research Site - Lyon
- Research Site - Villejuif
- Research Site - Meldola
- Research Site - Naples
- Research Site - Ravenna
- Research Site - Roma
- Research Site - Amsterdam
- Research Site - Lisbon
- Research Site - Porto
Tennessee
- Research Site - Chattanooga
- Research Site - Nashville
Michigan
- Research Site - Detroit
New York
- Research Site - New York
North Carolina
- Research Site - Chapel Hill
Rhode Island
- Research Site - Providence
Virginia
- Research Site - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 401 participants |
| Start Date | 2018-04-24 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 1 |
What the registry record for NCT03530397 still lists
NCT03530397 is an interventional study that assigns participants to a tested intervention. The registered 401 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (568% higher).
The record links to 1 condition, with Selected Advanced Solid Tumors appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT03530397 names 20 study sites across 7 states, led by Other, Tennessee, Michigan.
Frequently Asked Questions
What is clinical trial NCT03530397 about?
NCT03530397 is a clinical study titled "A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors". The purpose of this study is to evaluate MEDI5752 and carboplatin and pemetrexed or paclitaxel or nab-paclitaxel in adult subjects with advanced solid tumors, when administered as a single agent or combined with chemotherapy.
What is the current status of trial NCT03530397?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 401 participants. The study started on 2018-04-24. Estimated completion is 2025-12-30.
What conditions does trial NCT03530397 study?
This clinical trial studies the following conditions: Selected Advanced Solid Tumors.
What interventions are being tested in trial NCT03530397?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Carboplatin (DRUG), Pemetrexed (DRUG), MEDI5752 (BIOLOGICAL), Paclitaxel or Nab-Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT03530397?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03530397 being conducted?
This trial has 20 study locations across Michigan, New York, North Carolina, Rhode Island, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03530397's enrollment target sits among peer trials
401 75th of 2000 higher than 1,926 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04464226 · 402 participants · Phase 3
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
- NCT05183763 · 402 participants · NA
Medication Adherence Program
- NCT06748222 · 402 participants · Phase 3
E-Mindfulness Approaches for Living After Breast Cancer
- NCT06896474 · 402 participants · NA
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI